1227360-87-3

Upstream product

• 1427311-07-6 C₂₁H₂₃BrClN₃O₄ 
• 1427311-09-8 C₂₄H₂₄ClN₅O₃ 
• 16313-66-9 5-bromoanthranilamide 
• 501-81-5 pyridyl-3-yl-acetic acid 
• 1227360-76-0 C₁₉H₁₆ClN₅O 
• 57292-44-1 N-Boc-D-(4-Cl)Phe-OH 
• 1227360-76-0 (R)-2-(1-amino-2-(4-chlorophenyl)ethyl)-6-(1H-pyrazol-4-yl)quinazolin-4-ol 

Relevant academic research and scientific papers

Amino acid derived quinazolines as Rock/PKA inhibitors

SAR and lead optimization studies for Rock inhibitors based on amino acid-derived quinazolines are described. Studies demonstrated that these amino acid derived quinazolinones were mainly pan-Rock (I & II) inhibitors. While selectivity against other kinas

QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS

The invention is directed to quinazoline compounds that can inhibit the bioactivity of one or more kinase enzymes, including a Rho kinase, an AKT kinase, a p70S6K kinase, a LIM kinase, an IKK kinase, a Fit kinase, an Aurora kinase, or a Src kinase, or any combination thereof; to methods of use of those compounds; and to methods of preparation of those compounds. The inventive compounds can be used in the treatment of malconditions including cardiovascular disease, neurogenic pain, hypertension, atherosclerosis, angina, stroke, arterial obstruction, peripheral arterial disease, erectile dysfunction, acute and chronic pain, dementia, Alzheimer's disease, Parkinson's disease, neuronal degeneration, asthma, amyotrophic lateral sclerosis, spinal cord injury, rheumatoid arthritis, osteoarthritis, osteoporosis, psoriasis, cerebral vasospasm, open angle glaucoma, multiple sclerosis, pulmonary hypertension, acute respiratory distress syndrome, inflammation, diabetes, urinary organ diseases and benign prostatic hypertrophy (BPH), metastasis, cancer, glaucoma, ocular hypertension, retinopathy, autoimmune disease, viral infection, or myocardial pathology.